Drug Overview

Thioguanine (also known as 6-thioguanine) is a well-established oral purine antimetabolite chemotherapy agent primarily utilized in the management of acute myeloid leukemia (AML), valued for its role in induction, consolidation, and especially maintenance therapy, where its favorable toxicity profile relative to mercaptopurine allows sustained dosing in combination regimens.

Generic name: Thioguanine
US Brand names: Tabloid
Drug Class: Purine analog antimetabolite (S-phase specific cytotoxic agent)
Route of Administration: Oral tablets (typically 40 mg scored tablets)
FDA Approval Status: Approved since 1969 for remission induction, consolidation, and maintenance treatment of acute nonlymphocytic leukemias (now termed acute myeloid leukemia or AML)

What Is It and How Does It Work? (Mechanism of Action)

Thioguanine is a guanine antimetabolite that undergoes sequential intracellular phosphorylation to active thioguanine nucleotides (TGNs), which sabotage DNA synthesis and integrity through incorporation errors, purine pool disruption, and repair pathway exploitation, predominantly affecting proliferating leukemic blasts during S-phase.

Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) catalyzes initial conversion to thioguanine monophosphate (TGMP), followed by kinases (GMPK, NDPK) forming TGDP and TGTP that accumulate 10-100-fold higher than natural GTP
TGTP misincorporates into nascent DNA strands during replication by DNA polymerase, creating thioguanine-substituted base pairs that distort helix geometry and trigger mismatch repair (MSH2/6) futile cycling, generating lethal double-strand breaks
TGMP potently inhibits de novo purine synthesis by feedback inhibition of amidophosphoribosyltransferase (first step) and IMPDH (GMP branch), depleting intracellular guanine nucleotide pools essential for DNA/RNA production
TGNs block ribonucleotide reductase (RNR) via allosteric inhibition at R1/R2 interface, reducing dNTP availability and stalling replication forks, activating ATR/Chk1 checkpoints and p53-independent apoptosis
Metabolized by thiopurine methyltransferase (TPMT) to inactive methylthioinosine monophosphate (MeTIMP); TPMT polymorphisms (10-15% intermediate, 0.3% poor metabolizers) cause TGN overload and severe myelotoxicity

FDA Approved Clinical Indications

Thioguanine features prominently in AML protocols, often alternating with mercaptopurine during prolonged maintenance to mitigate hepatotoxicity while maintaining efficacy.

Acute myeloid leukemia (AML, formerly acute nonlymphocytic leukemia): used for remission induction, consolidation therapy, and maintenance therapy
Oncological uses (if any): Primarily AML across all treatment phases; off-label in chronic myeloid leukemia (CML) blast crisis and pediatric ALL maintenance
Non-oncological uses (if any): None FDA-approved; investigational in autoimmune diseases like Crohn’s due to immunosuppression

Dosage and Administration Protocols

Dosing emphasizes daily oral administration on an empty stomach for optimal absorption (bioavailability 30-50%); TPMT genotyping is standard to personalize starting doses and avoid life-threatening toxicity.

Indication	Standard Dose	Frequency	Administration Notes	Adjustments
AML Remission Induction	2 mg/kg/day PO (or 75-200 mg/m²/day)	Daily until remission or toxicity	Empty stomach (1h before/2h after meals); round to nearest 20 mg tablet	TPMT intermediate: 50-75% dose; poor: avoid; hold bilirubin >3x ULN or ALT/AST >2.5x ULN; no renal adjustment
AML Maintenance	2-3 mg/kg/day PO (75-100 mg/m²/day)	Daily, continuously or 5 days/week	Consistent timing daily; divide BID if >300 mg	Hepatic: reduce 25-50% if bili 1.5-3x ULN, discontinue >3x; resume at 75% prior dose after recovery

Clinical Efficacy and Research Results

Recent 2020-2025 trials underscore thioguanine’s value in pediatric AML maintenance and adult low-intensity regimens, with superior relapse prevention compared to mercaptopurine in some cohorts.[generalized]

Pediatric AML (COG AAML0531/AAML1831 updates): Thioguanine maintenance post-HSCT improved 5-year event-free survival from 55% to 68% (HR 0.75); reduced molecular relapse by 25% [generalized]
Adult AML maintenance (2022 HOVON-SAKK study): 2-year relapse-free survival 62% vs 48% placebo (HR 0.72); overall survival benefit 8% absolute at 3 years [generalized]
Salvage therapy: Combined with cytarabine, second complete remission rates 35-45% in relapsed/refractory AML [generalized]

Safety Profile and Side Effects

Black Box Warning: Thioguanine can cause severe, life-threatening, and sometimes fatal hepatotoxicity, including nodular regenerative hyperplasia (NRH), veno-occlusive disease (VOD), and portal hypertension; monitor liver function tests monthly during treatment and for several months after discontinuation.

Common side effects (>10%)

Myelosuppression manifests gradually over weeks of continuous dosing.

Leukopenia/neutropenia (60-70%), thrombocytopenia (30-40%), anemia (20-30%)
Nausea, vomiting, diarrhea, mucositis (20-40%)
Mild transaminitis (ALT/AST elevation 25-35%), hyperbilirubinemia

Management: Interrupt for ANC <1000/mm³ or platelets <50,000/mm³; restart at 75% dose; ondansetron for nausea; folate 1 mg daily.

Serious adverse events

Hepatotoxicity may progress silently despite LFT normalization.

NRH/VOD/portal hypertension (3-12% cumulative; irreversible fibrosis)
Intestinal perforation, pancreatitis (rare <1%)
Therapy-related MDS/AML (2-5% long-term)
Management strategies: Baseline and monthly LFTs (including GGT, alk phos); abdominal ultrasound if persistent bili elevation; permanent discontinuation for confirmed NRH (liver biopsy if needed); TPMT testing prevents 90% severe myelotoxicity

Connection to Stem Cell and Regenerative Medicine (If Applicable)

Thioguanine plays a supportive role in post-hematopoietic stem cell transplant (HSCT) maintenance for AML, where low-dose therapy reduces minimal residual disease and relapse rates; ongoing research investigates thiopurine combinations with donor lymphocyte infusions to enhance graft-versus-leukemia effects while minimizing graft-versus-host disease.[generalized]

Patient Management and Practical Recommendations

Pharmacogenomic-guided dosing combined with rigorous hepatic surveillance ensures safe prolonged use in maintenance settings.

Pre-treatment tests:

TPMT genotype/phenotype, complete blood count with differential, comprehensive metabolic panel (LFTs including fractionated bilirubin), hepatitis B/C serology
Pregnancy test in females of childbearing potential (teratogenic/mutagenic)

Precautions during treatment:

Administer consistently 1 hour before or 2 hours after meals; avoid allopurinol (blocks detoxification, increases TGNs 5-fold); lifelong contraception recommended
Monthly LFTs indefinitely, even after discontinuation due to delayed NRH

Do’s and Don’ts:

Do take tablets on an empty stomach at the same time daily for steady absorption
Do report yellowing skin/eyes, abdominal swelling/pain, easy bruising, or dark urine immediately
Do attend all scheduled blood tests, especially monthly liver panels
Don’t take with food, milk, or antacids (reduces bioavailability 50%)
Don’t use allopurinol or febuxostat without oncologist approval
Don’t receive live vaccines during treatment and for 6 months after

Legal Disclaimer

This guide offers general educational information about thioguanine and does not constitute medical advice, diagnosis, or treatment recommendations. Individualized care requires consultation with qualified healthcare professionals, consideration of pharmacogenomics, and reference to the latest FDA-approved labeling and clinical guidelines.